Assessing Sandy's Impact on the Bond Markets
Delayed by the storm, new issuance surged late last week. Plus, we examine the credit impact on utilities and munis.
The corporate bond market was essentially shut down last Monday and Tuesday and was dislocated on Wednesday. However, the new issue market came back with a vengeance on Thursday and Friday. The total amount of bonds priced for issuers we cover topped $19 billion, one of the largest two-day totals that we can remember.
While the market appeared to be able to handle this surge of new issues, this next week should be instructive as to the near-term outlook for the market. Abbott Labs ABT (UR-) subsidiary AbbVie is expected to issue more than $10 billion of notes in order to upstream cash to the parent company before being spun off into a stand-alone entity. This deal size is one of the largest investment-grade transactions, and how well the transaction is received and trades in the secondary market may affect the short-term direction of the corporate bond market.
David Sekera does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.